Enzo to Market Nuclea's Metastatic Breast Cancer Dx | GenomeWeb

NEW YORK (GenomeWeb News) – Enzo Clinical Labs and Nuclea Biotechnologies have entered into an agreement to market Nuclea's non-invasive HER-2/neu serum test for monitoring metastatic breast cancer, Enzo Biochem announced today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

It's too difficult to correct or retract a flawed scientific paper, researchers write in Nature.

A proposed bill would require NSF to only fund research that's in "the national interest."

Australia's Commonwealth Scientific and Industrial Research Organisation plans to eliminate up to 350 jobs.

In PLOS this week: researchers explore the transfer of host genetic material into viruses, and more.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.